PTC Therapeutics
PTCT · NASDAQ
Bulios Fair Price
$81.96
29.2% upside
Current Price
$63.46
According to Bulios Fair Price, PTCT is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
PTC Therapeutics, Inc. is an American biotechnology company that specializes in the development and commercialization of drugs for genetic and rare diseases. Founded in 1998, the company focuses on molecular therapies and innovative approaches to treating conditions that lack sufficient treatment options. PTC Therapeutics is dedicated to researching and developing drugs that target the genetic mechanisms of diseases, including conditions like Duchenne muscular dystrophy and other rare genetic disorders. The company has a global reach, with its drugs distributed in various countries.
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew Klein
Employees
991
Headquarters
Warren
Upcoming events
Earnings
Upcoming earnings report